HOUSTON, Aug. 24 /PRNewswire/ -- OrthoAccel Technologies, Inc. announced this week that it has finalized distributionagreements with two key partners: AB Orthodontics Pty Ltd in Melbourne, Australia, and Inno Dental and Medical Corporation (Inno DMC), based in Seoul, South Korea.
The AcceleDent System is currently being sold to select orthodontic specialists in the United Kingdom, where it was introduced last year through a limited release market program. The lightweight device, used to speed up the rate of orthodontic treatment, is intended for 20 minutes of daily use. Patients simply bite down on the Mouthpiece to hold it in place, which allows freedom of the hands to engage in other routine, daily activities during the treatment session. Patients have reported using the device while engaged in a variety of activities, including homework, watching television and commuting to work. The Company has reported plans for a general market release in the United Kingdom in September, at the British Orthodontic Conference in Brighton.
Mike Kaufman, VP of Marketing and Business Development for OrthoAccel commented, "Australia and South Korea are key international markets for us and allow us to develop product awareness and success stories in advance of a future release in other international markets and the United States."
This definitive distribution agreement between OrthoAccel and AB Orthodontics formalizes the intent to partner together that was reported by the two companies in May. " The AcceleDent device has received much positive interest from the Australian orthodontic community including academics and researchers. Some orthodontists have reported excellent initial results, especially in cases where tooth movement has been very slow or virtually unachievable," stated Andrew Binns, Managing Director. On October 18-22 AB Orthodontics is preparing to host AcceleDent seminars in Sydney, Melbourne and Brisbane with Dr. Asif Chatoo as the keynote speaker. Dr Chatoo, who practices at the Lingual Orthodontic Clinic, was among the first users of the AcceleDent System in the United Kingdom.
The agreement with Inno DMC marks OrthoAccel's first movement into the Asia Pacific region. Mr. Sung-ku Hong, CEO of Inno DMC, commented, "AcceleDent is an exciting and new innovative technology with the potential to offer significant time savings to the patient and practice efficiencies to the orthodontist." Mike Kaufman added, "OrthoAccel first had the opportunity to meet with Mr. Hong during the 2010 AAO meeting and we immediately appreciated the depth and experience of Inno DMC and how their relationships with the orthodontic community would benefit our efforts in South Korea." Although commercial sales are not anticipated until next year because regulatory details must be finalized, efforts to begin increasing awareness and educating dental professionals will begin immediately.
OrthoAccel is anticipating the conclusion of another US clinical trial at the UT Health Science Center in San Antonio with a target completion date later in 2010.
About OrthoAccel Technologies, Inc.
Based in Houston, Texas, OrthoAccel Technologies, Inc. is a privately owned medical device company currently engaged in the development, manufacturing, and marketing of products to enhance dental care and orthodontic treatment.
About the AcceleDent System
AcceleDent represents the first clinical approach to safely accelerate orthodontic tooth movement via modulating biology. The device has been studied clinically and applies gentle pulsing forces in combination with standard orthodontics to move teeth faster through accelerated bone remodeling. Importantly, the device works complementary with all existing orthodontic technologies. AcceleDent is neither FDA cleared nor FDA approved; it is currently investigational only in the United States. More information can be found at www.acceledent.com or requested via email@example.com
SOURCE OrthoAccel Technologies, Inc.
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All